Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2015

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2015’, provides an overview of the Metastatic Hepatocellular Carcinoma (HCC)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Hepatocellular Carcinoma (HCC) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Hepatocellular Carcinoma (HCC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Hepatocellular Carcinoma (HCC) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Metastatic Hepatocellular Carcinoma (HCC) Overview
Therapeutics Development
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies
Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes
Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Celgene Corporation
F. Hoffmann-La Roche Ltd.
HanAll Biopharma Co., Ltd.
Incuron, LLC
Johnson & Johnson
MedImmune, LLC
Mirna Therapeutics, Inc.
Novartis AG
OncoMed Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc.
Pfizer Inc.
PharmAbcine, Inc.
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AV-203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-9150 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-122 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Metastatic Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
codrituzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dusigitumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL-143 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ipafricept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-42756493 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mepacrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-34 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oprozomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OSU-2S - Drug Profile
Product Description
Mechanism of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pasireotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pentamidine isethionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-04518600 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
temsirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TTAC-0001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UPO-901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Hepatocellular Carcinoma (HCC) - Recent Pipeline Updates
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products
Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones
Featured News & Press Releases
Nov 20, 2014: ISIS-STAT3 Rx Data Presented by AstraZeneca at European Cancer Symposium
Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio
May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2015
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca Plc, H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Celgene Corporation, H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Incuron, LLC, H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Johnson & Johnson, H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MedImmune, LLC, H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Pfizer Inc., H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by PharmAbcine, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Recent Pipeline Updates, H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H2 2015
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2015
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook